相关实验视频

Updated: May 22, 2025

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Published on: September 6, 2017

血液学和分子反应对rope-interferon alfa-2b治疗真多细胞血症:从前性研究的48周结果

Seug Yun Yoon¹, Sung-Soo Yoon², Deok-Hwan Yang³

¹Division of Hematology & Medical Oncology, Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Seoul, Korea.

International journal of cancer

|March 15, 2025

概括

获得完整的血液学反应 (CHR) 和分子反应 (MR) 是与多细胞血症患者 (PV) 相关的,这些患者接受了rope-interferon alfa-2b治疗. 这项研究强调了这些反应之间的联系,以改善疾病管理.

科学领域:

血液学血液学血液学
在瘤学瘤学.
药理学药理学是指药理学的学科.

背景情况:

多细胞血症 (PV) 的管理旨在预防血栓形成,而完全的血液学反应 (CHR) 是一个关键目标.
通过分子反应 (MR) 表示的减少JAK2 V617F突变负担,对其潜在的疾病修饰作用越来越感兴趣.

研究的目的:

在患有多细胞真血病 (PV) 的患者中,评估完整的血液学反应 (CHR) 和分子反应 (MR) 之间的关联.
为了评估rope-interferon alfa-2b在实现PV患者中CHR和MR的疗效.

主要方法:

一个第2阶段,单臂,开放标签试验,涉及99名PV患者,在48周内接受皮下用罗佩干扰素α-2b治疗.
在最初的5周内,从250微克升至500微克的rope-interferon alfa-2b剂量升级.
在多个时间点对CHR和MR率的评估,长达48周.

主要成果:

在12周,CHR的发病率从27%上升到48周的63%.
MR 发病率表现出类似的趋势,从 12 周的 32% 增加到 48 周的 57%.
在48周CHR和MR之间发现了显著的正相关性 (Phi系数=0.6146,p<.0001).

结论:

在PV患者中,用Ropeginterferon alfa-2b治疗与实现CHR和MR有关.
这些发现表明,CHR和MR是使用这种干扰素治疗的PV患者的相关结果.
亚组分析表明,在耐氨酸素/不耐氨酸素的患者和之前未服用氨酸素的患者中,CHR的发病率相似.

关键词:

人类健康委员会 (CHR)这就是为什么MR MR MR.协会协会协会协会协会维拉多细胞血症维拉多细胞血症干扰素阿尔法-2bb的使用.

更多相关视频

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

Published on: February 16, 2024

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

相关概念视频

Role of Hematopoietic Growth Factors

Role of Hematopoietic Growth Factors

Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...

Regulation of Hematopoietic Stem Cells

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...